Need Help?
Copied to clipboard!

SMARCA4 Loss in STK11/KEAP1 Co-Mutant Lung Adenocarcinoma

We investigated SMARCA4 loss-of-function in lung adenocarcinoma (LUAD) alone and combined with inactivation of STK11 and KEAP1, through analysis of clinicogenomic datasets, transcriptomic profiling of clinical samples, transcriptomic profiling, and in vitro and in vivo functional characterization of isogenic cell line models. We associated poor prognosis, higher metastatic burden, and therapeutic recalcitrance with SMARCA4/STK11/KEAP1 triple mutant LUAD, identified upregulation of TGF-β-associated genes as a shared feature between triple mutant clinical samples and models, and captured enhanced metastatic behaviors in triple mutant models.

We also interrogated the frequencies of co-occurrence and mutual exclusivity of canonical LUAD driver mutations (in genes like KRAS, EGFR, etc.) to further characterize the clinical and molecular features of SMARCA4/STK11/KEAP1 triple mutant LUAD--a co-mutationally defined LUAD subset at the focus of this manuscript and rarely captured in similar clinical sequencing-based studies. We additionally noted these drivers in the characterization of samples in our clinical RNA-Seq dataset as a way to examine the similarity of this more focused analysis to our larger clinical sequencing cohort.

The data available through dbGaP are bulk RNA-Seq of LUAD tumor samples analyzed in this study.